ABSTRACT
OBJECTIVE: To determine the influence of various patient-specific factors, use of concomitant medications, and weekly vitamin K intake on total weekly warfarin maintenance dose (TWD). METHODS: Information collected, via retrospective chart review, included TWD, general demographics, vitamin K consumption, target INR range, use of alcohol, tobacco, and cytochrome P450 (CYP)-inducing medications, and concomitant medications and diseases. RESULTS: The majority of patients (n = 131) were Caucasian (71%), with more females (55%) than males. Use of CYP-inducing medications resulted in the largest correlation coefficient (r = 0.30). The sample was divided into high warfarin dose (TWD >/= 50 mg) and low warfarin dose (TWD = 25 mg) patient populations to discern areas where the two populations differed. Age and amiodarone use were the only statistically significant differences between the two groups, with high dose patients tending to be younger and to use less amiodarone. Age and CYP-inducing medications were found to be the only statistically significant predictors of TWD in the regression analysis. The TWD was 2.4 mg less for each additional decade of patient age. The coefficient on CYP-inducing medications indicates that the concomitant use of a CYP inducer is associated with an increase in TWD of 17.2 additional milligrams, adjusting for all other variables in the model. CONCLUSION: We found concomitant use of CYP inducer, age, height, and ethnicity to have the greatest influence on TWD. Positive relationships were found between TWD and the use of CYP450 inducer, height, and African American ethnicity. Although it did appear that women required a lower TWD than men, this factor contributed mildly. Further studies with a greater sample size may more precisely predict the effect of patient-specific factors on TWD, thus uncovering additional relationships.
ABSTRACT
UNLABELLED: The purpose of this one-year observational study was to evaluate quality of life in patients at the Medical University of South Carolina Family Medicine clinic who were followed by a clinical pharmacist diabetes educator. METHODS: Patients who have been seen by the clinical pharmacist for diabetes education and management services were contacted by telephone and asked to complete a previously validated Diabetes-related Quality of Life (DRQL) survey. In addition, the patient's most recent hemoglobin A1C, blood pressure, fasting lipid panel and aspirin use were obtained from the electronic medical record. Correlation and logistic regression analysis was completed in order to assess the quality of life score and clinical outcomes. RESULTS: A total of 47 patients completed the survey (37%). The median overall score was 1 (1-very satisfied; 5-very dissatisfied). Patients who were more satisfied with their current treatment tended to have lower LDL, systolic and diastolic blood pressure (BP) values (r=0.32, 0.3, 0.33; p=0.03, 0.03, 0.02). In addition, patients taking more medications were more dissatisfied with the amount of time spent managing their disease (r=0.29, p=0.04), felt more pain associated with the treatment of their disease (r=0.32, p=0.02), and were more worried that their body looked different as a result of their diabetes (r=0.32, p=0.02). CONCLUSION: Patients in this clinic were highly satisfied with their quality of life. The authors found that trends exist for relationships between several important clinical parameters and quality of life.